¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦25Â÷ ¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú ¿¬¼ö°­Á : Severe and intractable respiratory disease : 2023-06-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦25Â÷ ¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú ¿¬¼ö°­Á : Severe and intractable respiratory disease : 2023-06-10
±³À°ÀÏÀÚ : 2023-06-10
±³À°Àå¼Ò : µ¿°ü 6Ãþ ´ë°­´ç

±³À°ÁÖÁ¦ : Á¦25Â÷ ¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú ¿¬¼ö°­Á : Severe and intractable respiratory disease

ÁÖÃÖ±â°ü : ¼­¿ï¾Æ»êº´¿ø
´ã´çÀÚ : ±èÀº¿µ
¿¬¶ôó : 02-3010-3130  

À̸ÞÀÏ : plm3010@amc.seoul.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 60,000¿ø  

ºñ°í 1.Àü¹®ÀÇ »çÀüÁ¢¼ö 50,000¿ø ÇöÀåÁ¢¼ö 60,000¿ø2. ÀüÀÓÀÇ, Àü°øÀÇ ¹× °£È£»ç, ±âŸ µî »çÀüÁ¢¼ö 40,000¿ø ÇöÀåÁ¢¼ö 50,000¿ø

±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 09:00~09:25 Refractory chronic cough: Mechanisms and treatment updates ¼Û¿ìÁ¤(¼­¿ï¾Æ»êº´¿ø ¾Ë·¹¸£±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 09:25~09:50 The optimal treatment of MAC pulmonary disease Á¶°æ¿í(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 09:50~10:15 Beyond inhaler: non-pharmacologic treatment in COPD À̼¼¿ø(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

ÈÞ½Ä 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 10:15~10:30 COFFEE BREAK ()

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 10:30~10:40 Importance of accurate nodal staging in stage III NSCLC Áö¿øÁØ(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 10:40~11:05 Optimal strategy of surgical treatment in stage III NSCLC À±À籤(¼­¿ï¾Æ»êº´¿ø ½ÉÀåÇ÷°üÈäºÎ¿Ü°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 11:05~11:30 Update of perioperative chemotherapy in stage III NSCLC À±½Å±³(¼­¿ï¾Æ»êº´¿ø Á¾¾ç³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 11:30~11:55 Current practice of radiation therapy in stage III NSCLC ½Å¿µ¼·(¼­¿ï¾Æ»êº´¿ø ¹æ»ç¼±Á¾¾çÇаú)

½Ä»ç 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 11:55~13:00 LUNCH ()

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 13:00~13:25 Updated IPF guideline and PPF (progressive pulmonary fibrosis : radiologic aspect äÀºÁø(¼­¿ï¾Æ»êº´¿ø ¿µ»óÀÇÇаú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 13:25~13:50 Hopes and concerns about PAH targeted therapy in PH-ILD ÀÌÀç½Â(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 13:50~14:15 Lung transplantation in ILD patients ±èȣö(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

ÈÞ½Ä 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 14:15~14:30 COFFEE BREAK ()

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 14:30~14:55 Effect of corticosteroid therapy in severe pneumonia and ARDS ÇãÁø¿ø(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 14:55~15:20 Severe viral pneumonia other than COVID-19 ÃÖ»óÈ£(¼­¿ï¾Æ»êº´¿ø °¨¿°³»°ú)

±³À°½Ã°£ 06¿ù 10ÀÏ µ¿°ü6Ãþ ´ë°­´ç 15:20~15:45 Treatment of moderate to severe ARDS ¾ÈÁöȯ(¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦25Â÷ ¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú ¿¬¼ö°­Á : Severe and intractable respiratory disease : 2023-06-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѼҾÆÀçÈ°¹ß´ÞÀÇÇÐȸ Çмú´ëȸ : 2023-06-10
´ÙÀ½±Û 2023³â ¼­¿ï¾Æ»êº´¿ø ³úÁ¹Áß ½ÉÆ÷Áö¾ö From Basic Principles to Advanced Techniques : 2023-06-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
63 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø Á¦7ȸ Áö¿ª»çȸº´¿ø°ú ÇÔ²²ÇÏ´Â °¨¿°°ü¸® ½ÉÆ÷Áö¿ò : 2018-08-18 0 888 2018-07-28
62 ¼­¿ï 2018 ÇÏ°è ºÐÀÚÆó¾Ï¿¬±¸È¸ Àӻ󿬱¸ ¿öÅ©¼ó : 2018-08-18 0 543 2018-07-28
61 ¼­¿ï ´ëÇÑ¿Ü°úÃÊÀ½ÆÄÇÐȸ ÃÊÀ½ÆÄ °Ë»ç ±Ç°í¾È ½ÉÆ÷Áö¾ö : 2018-08-18 0 776 2018-07-28
60 ºÎ»ê 2018³â ´ëÇѼÒÈ­±â¿¬°üÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2018-08-18 0 675 2018-07-28
59 ¼­¿ï ´ëÇÑ»êºÎÀΰúÀÇ»çȸ&Çѱ¹¹ß»ý»ý¹°ÇÐȸ Joint Symposium : 2018-08-18 0 1,081 2018-07-28
58 ¼­¿ï ´ëÇѺ´¸®ÇÐȸ 8th Ç÷¾×º´¸® ¿¬¼ö±³À° : 2018-08-18 0 715 2018-07-28
57 ¼­¿ï ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18 0 842 2018-07-28
56 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ 2018³âµµ Á¦2Â÷ ÁöµµÀü¹®ÀÇ ±³À° : 2018-08-17 0 857 2018-07-28
55 °­¿ø ´ëÇѽÉÀåÇÐȸ Ç÷°ü¿¬±¸È¸ ÇÏ°è½ÉÆ÷Áö¾ö : 2018-08-17 0 1,286 2018-07-28
54 ¼­¿ï Á߾Ӵ뺴¿ø »êºÎÀΰú žÆÃÊÀ½ÆÄ ¿¬¼Ó°­Á : 2018-08-16 0 659 2018-07-28
53 ¼­¿ï °Ç±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö±³À°(ÈĵÎÁúȯ) : 2018-08-16 0 728 2018-07-28
52 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] °Ç°­º¸Çè ¼ö°¡°áÁ¤ : 2018-08-16 0 865 2018-07-28
51 ¼­¿ï Çѱ¹¿ªÇÐȸ Biomarker ¸¦ ÀÌ¿ëÇÑ ¿¬±¸ ¼³°è¿Í ºÐ¼® : 2018-08-14 0 1,277 2018-07-28
50 ¼­¿ï Á¦240ȸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿ù·Ê ÇмúÁý´ãȸ : 2018-08-14 0 423 2018-07-28
49 ¼­¿ï Çѱ¹¿ªÇÐȸ MR ±â¹Ý À¯Àüü ¿ªÇבּ¸¿Í °ø°ø°Ç°­ÀÚ·á ±â¹Ý Outcome research : 2018-08-13 0 646 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷